Generic Capex Availability
Capex is a brand name of fluocinolone topical, approved by the FDA in the following formulation(s):
CAPEX (fluocinolone acetonide - shampoo; topical)
-
Manufacturer: GALDERMA LABS LP
Approval date: August 27, 1990
Strength(s): 0.01% [RLD]
Has a generic version of Capex been approved?
No. There is currently no therapeutically equivalent version of Capex available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Capex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with Capex.
See also...
- Capex shampoo Consumer Information (Wolters Kluwer)
- Capex Consumer Information (Cerner Multum)
- Capex Advanced Consumer Information (Micromedex)
- Fluocinolone cream Consumer Information (Wolters Kluwer)
- Fluocinolone oil Consumer Information (Wolters Kluwer)
- Fluocinolone oil (body oil) Consumer Information (Wolters Kluwer)
- Fluocinolone oil (scalp oil) Consumer Information (Wolters Kluwer)
- Fluocinolone shampoo Consumer Information (Wolters Kluwer)
- Fluocinolone solution Consumer Information (Wolters Kluwer)
- Fluocinolone topical Consumer Information (Cerner Multum)
- Fluocinolone topical oil Consumer Information (Cerner Multum)
- Fluoderm Mild Cream Advanced Consumer Information (Micromedex)
- Fluoderm Mild Ointment Advanced Consumer Information (Micromedex)
- Fluoderm Regular Cream Advanced Consumer Information (Micromedex)
- Fluoderm Regular Ointment Advanced Consumer Information (Micromedex)
- Fluolar Mild Advanced Consumer Information (Micromedex)
- Fluolar Regular Advanced Consumer Information (Micromedex)
- Fluonide Mild-Cream Advanced Consumer Information (Micromedex)
- Synamol Advanced Consumer Information (Micromedex)
- Fluocinolone Topical application Advanced Consumer Information (Micromedex)
- Fluocinolone Acetonide topical AHFS DI Monographs (ASHP)
- Fluocinonide topical AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
